You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Offshore Wind Energy Resource Siting
SBC: SEALANDAIRE TECHNOLOGIES, INC. Topic: 911SGOver the last decade, it has been noted that offshore wind energy resource development could prove extensively valuable in many areas of our nation’s growth, including continued diversification of our energy supply, more options for cost-competitive electricity in coastal and Great Lakes regions, and economical stimulation through new and lasting infrastructure development. The challenges associ ...
SBIR Phase I 2013 Department of CommerceNational Oceanic and Atmospheric Administration -
Development of Noninvasive System for Detection of Sleep Apnea in Animals
SBC: NEOGENE BIOSCIENCES, LLC Topic: NIADESCRIPTION (provided by applicant): The long term goal of this project is to develop and commercialize noninvasive equipment, called the sleep and respiratory track (SARTrak) system, for high throughput detection of sleep apnea in animals. The specific goal for the Phase I application is to design and evaluate a basic model of the SARTrak system with eight chambers (one chamber per animal), i.e. ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Advanced Nitric Oxide Release Bactericidal Urinary Catheters
SBC: BIOCREDE INC. Topic: NIDDKDESCRIPTION (provided by applicant): We propose a novel and competitive urinary tract silicone Foley catheter made from a proprietary polymeric formulation to effectively reduce catheter-associated urinary tract infections (CAUTI) via nitric oxide (NO) release. Preliminary studies show that the device will be able to: (1) continuously deliver NO at rates enough to maintain bactericidal properties ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Reduction of Tunneled Dialysis Catheter Dysfunction Via Long Term Nitric Oxide Re
SBC: BIOCREDE INC. Topic: NIDDKDESCRIPTION (provided by applicant): We propose a novel and price competitive Tunneled Dialysis Catheter (TDC) made from a proprietary polymeric formulation to effectively reduce TDC dysfunction via long-term nitric oxide (NO) release, particularly duringthe period of AVF maturation in incident hemodialysis and TDC dependent patients. Preliminary studies with polymer materials used to prepare exis ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Lighting System for Premature Infant Incubators
SBC: WHITE BRIAR CORPORATION Topic: NICHDProject Summary Incubators have been in use since the 19th century and have significantly improved survival for premature infants. However, incubator lighting systems still can still be improved. Proposed is a project to develop and test the feasibility and acceptability of a solid state lighting (SSL) system for use with neonatal intensive care unit (NICU) incubators. The system would 1) promote ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Point-of-Care Carotid Ultrasound and Cardiovascular Risk Assessment Device
SBC: ARBOR ULTRASOUND TECHNOLOGIES, LLC Topic: NHLBIDESCRIPTION (provided by applicant): This proposal describes a novel, low-cost, high-performance compact carotid ultrasound imaging system to meet the clinical point-of-care needs for stenosis assessment based upon consensus practice criteria guidelines. At the same time, this system will meet the growing need for advanced cardiovascular (CV) risk assessment. This research integrates proven fundam ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Coronary Post-Dilatation Catheter
SBC: P2D, INC Topic: NIADESCRIPTION (provided by applicant): The goal of this proposal is to develop tumor necrosis factor (TNF )-inhibiting compounds as neuroprotectant drugs for treating Alzheimer's disease (AD). Current FDA-approved AD interventions are symptomatic treatments with limited efficacy which do not affect AD etiology or modify the course of disease progression. Thus, a critical need exists for a nov ...
SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Broad Spectrum Antiviral Nucleoside Phosphonate Analogs
SBC: TSRL, INC. Topic: NIAIDDESCRIPTION: The Working Group for Civilian Biodefense has identified orthopox DNA viruses such as variola as a potential bioterrorism threat, and numerous other DNA viruses, including herpes, adeno, pox, polyoma and papilloma viruses, are of general concern in a public health context, as are the possible emergence of new pathogens and the potential for development of drug resistance in existing s ...
SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Modular Ultrasonic Beacon System (MUBS) for Ultrasound-guided Interventional Surg
SBC: Nymirum, Inc. Topic: NIAMSDESCRIPTION: Myotonic dystrophy 1 (DM1) is the leading form of adult muscular dystrophy resulting in progressive neuromuscular effects. The disease affects 1 in 6000 people. Nymirum is interested in identifying a small molecule that can be used to slow oreliminate the progression of DM1. The cause of DM1 is the expansion of a CUG RNA sequence within the DMPK gene. This repeat RNA is toxic to no ...
SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Osteosarcoma in Dogs as a Model for the Development of Drugs to Treat Micro-metas
SBC: CYPRIS, LLC Topic: NCIDESCRIPTION (provided by applicant): This project will determine the efficacy of tetrathiomolybdate (TM), a potent copper- reducing compound to effectively inhibit angiogenesis and disrupt fatal micro-metastatic progression to vital organs common in humancancers. To evaluate TM's capacity in this role, a clinical trial will be conducted on dogs diagnosed with osteosarcoma (OS) of the leg bone ...
SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health